Inhaled iloprost for therapy in pulmonary arterial hypertension

被引：0

作者：

Ewert, Ralf ^{[1
]}

Glaeser, Sven ^{[1
]}

Bollmann, Tom ^{[1
]}

Schaeper, Christoph ^{[1
]}

机构：

[1] Ernst Moritz Arndt Univ Greifswald, Dept Internal Med, Greifswald, Germany

来源：

EXPERT REVIEW OF RESPIRATORY MEDICINE | 2011年 / 5卷 / 02期

关键词：

inhaled iloprost; PAH; prostanoids; side effects of therapy; therapy algorithm; CALCIUM-CHANNEL BLOCKERS; LONG-TERM TREATMENT; STABLE PROSTACYCLIN ANALOG; AEROSOLIZED ILOPROST; ORAL SILDENAFIL; COMBINATION THERAPY; NITRIC-OXIDE; BOSENTAN; PHARMACOKINETICS; PHARMACODYNAMICS;

D O I：

10.1586/ERS.11.14

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Iloprost (Ventavis (R), Bayer Schering Pharma, Germany) is a synthetic prostacyclin that is used in its inhalative form for the therapy of pulmonary arterial hypertension. Long-term therapy can increase exercise capacity and quality of life. The use of modern nebulizers especially designed for the administration of iloprost guarantees the pulmonary deposition of the required doses and systematically minimizes side effects. Regarding existing data, inhalative iloprost acts in effective and safe combination with other classes of medication; indeed, such combination therapy is frequently necessary in pulmonary arterial hypertension.

引用

页码：145 / 152

页数：8

共 56 条

[41] Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension [J].

Opitz, CF ;

Wensel, R ;

Winkler, J ;

Halank, M ;

Bruch, L ;

Kleber, FX ;

Höffken, G ;

Anker, SD ;

Negassa, A ;

Felix, SB ;

Hetzer, R ;

Ewert, R .

EUROPEAN HEART JOURNAL, 2005, 26 (18) :1895-1902

[42] INHALED NITRIC-OXIDE AS A CAUSE OF SELECTIVE PULMONARY VASODILATATION IN PULMONARY-HYPERTENSION [J].

PEPKEZABA, J ;

HIGENBOTTAM, TW ;

DINHXUAN, AT ;

STONE, D ;

WALLWORK, J .

LANCET, 1991, 338 (8776) :1173-1174

[43] Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment [J].

Petkov, V ;

Ziesche, R ;

Mosgoeller, W ;

Schenk, P ;

Vonbank, K ;

Stiebellehner, L ;

Raderer, M ;

Brunner, C ;

Kneussl, M ;

Block, LH .

THORAX, 2001, 56 (09) :734-736

[44] Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension [J].

Reichenberger, F. ;

Mainwood, A. ;

Doughty, N. ;

Fineberg, A. ;

Morrell, N. W. ;

Pepke-Zaba, J. .

RESPIRATORY MEDICINE, 2007, 101 (02) :217-222

[45] Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension [J].

Reichenberger, Frank ;

Mainwood, Ann ;

Morrell, Nicholas W. ;

Parameshwar, Jayan ;

Pepke-Zaba, Joanna .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2011, 24 (01) :169-173

[46] HIGH-DOSE CALCIUM-CHANNEL BLOCKING THERAPY FOR PRIMARY PULMONARY-HYPERTENSION - EVIDENCE FOR LONG-TERM REDUCTION IN PULMONARY ARTERIAL-PRESSURE AND REGRESSION OF RIGHT VENTRICULAR HYPERTROPHY [J].

RICH, S ;

BRUNDAGE, BH .

CIRCULATION, 1987, 76 (01) :135-141

[47] Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs [J].

Schermuly, RT ;

Schulz, A ;

Ghofrani, HA ;

Meidow, A ;

Rose, F ;

Roehl, A ;

Weissmann, N ;

Hildebrand, M ;

Kurz, J ;

Grimminger, F ;

Walmrath, D ;

Seeger, W .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (02) :741-745

[48]

Schulz A., 2006, ILOPROST INTENSIVE C

[49] Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy [J].

Seyfarth, HJ ;

Pankau, H ;

Hammerschmidt, S ;

Schauer, J ;

Wirtz, H ;

Winkler, J .

CHEST, 2005, 128 (02) :709-713

[50]

Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI [10.1016/j.jacc.2009.04.012, 10.1016/j.jacc.2013.10.029]

← 1 2 3 4 5 6 →